Defence Therapeutics Inc.

  • ISIN: CA24463V1013
  • Land: Canada

Alle Mitteilungen

DGAP-News 23.11.21 12:20 DGAP-News: Defence Therapeutics Inc.
Defence Therapeutics Inc.: EINLEITUNG DER HERSTELLUNG DES KREB[...]
DGAP-News 23.11.21 08:30 DGAP-News: Defence Therapeutics Inc.
DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTUR[...]
DGAP-News 09.11.21 17:10 DGAP-News: Defence Therapeutics Inc.
Defence Therapeutics Inc.: DEFENCE THERAPEUTICS BERUFT DR. RIA[...]
DGAP-News 09.11.21 08:30 DGAP-News: Defence Therapeutics Inc.
DEFENCE THERAPEUTICS APPOINTS DR. RIAM SHAMMAA TO ITS BOARD[...]
DGAP-News 03.11.21 08:30 DGAP-News: Defence Therapeutics Inc.
IMPFSTOFFERGEBNISSE: DEFENCE THERAPEUTICS GIBT ERFOLGREICHE[...]
DGAP-News 13.10.21 18:10 DGAP-News: Defence Therapeutics Inc.
BEI EINER IN VITRO-STUDIE ERHÖHEN DIE ACCUM(TM)-VARIANTEN V[...]
DGAP-News 13.10.21 08:30 DGAP-News: Defence Therapeutics Inc.
Defence Therapeutics Inc.: DEFENCE THERAPEUTICS ACCUMTM VARIAN[...]
DGAP-News 06.10.21 13:25 DGAP-News: Defence Therapeutics Inc.
DEFENCE THERAPEUTICS BEREITET SICH AUF PHASE I-STUDIE VOR, [...]
DGAP-News 06.10.21 08:30 DGAP-News: Defence Therapeutics Inc.
Defence Therapeutics Inc.: DEFENCE THERAPEUTICS PREPARES FOR P[...]
DGAP-News 29.09.21 08:30 DGAP-News: Defence Therapeutics Inc.
DEFENCE THERAPEUTICS FINALISIERT IHRE ZIELE ZUM START EINER[...]
DGAP-News 20.09.21 12:00 DGAP-News: Defence Therapeutics Inc.
DEFENCE THERAPEUTICS MELDET DEN ERFOLGREICHEN VERLAUF VON E[...]
DGAP-News 20.09.21 08:30 DGAP-News: Defence Therapeutics Inc.
DEFENCE THERAPEUTICS SUCCESSFULLY ENGINEERED AND TESTED A N[...]
DGAP-News 14.09.21 12:20 DGAP-News: Defence Therapeutics Inc.
DEFENCE THERAPEUTICS FÜHRT ERFOLGREICHE TESTS SEINES ACCUVA[...]
DGAP-News 14.09.21 08:30 DGAP-News: Defence Therapeutics Inc.
DEFENCE THERAPEUTICS SUCCESS IN TESTING IT'S COVID-19 ACCUV[...]
DGAP-News 07.09.21 11:20 DGAP-News: Defence Therapeutics Inc.
START EINES PROGRAMMS VON DEFENCE THERAPEUTICS ZUR ENTWICKL[...]
DGAP-News 07.09.21 08:30 DGAP-News: Defence Therapeutics Inc.
DEFENCE THERAPEUTICS DEVELOPMENT PROGRAM TO ENGINEER A NEW [...]
DGAP-News 31.08.21 13:00 DGAP-News: Defence Therapeutics Inc.
DEFENCE THERAPEUTICS REICHT PROVISORISCHE US-PATENTANMELDUN[...]
DGAP-News 31.08.21 08:30 DGAP-News: Defence Therapeutics Inc.
DEFENCE THERAPEUTICS FILES ACID-BASED HYDROGELS USA PROVISI[...]
DGAP-News 18.08.21 11:00 DGAP-News: Defence Therapeutics Inc.
DEFENCE THERAPEUTICS WÄHLT DIE BESTEN 8 ACCUM(TM)-VARIANTEN[...]
DGAP-News 18.08.21 08:30 DGAP-News: Defence Therapeutics Inc.
DEFENCE THERAPEUTICS SELECTS THE BEST 8 ACCUM(TM) VARIANTS [...]

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktuelle Research-Studie

Original-Research: Gold Mountain Mining Corp. (von hanseatic stock publishing UG (haftungsbeschränkt)): Gold Mountain Mining Corp.

29. November 2021